Ajanta Pharma Q2 FY27 consolidated revenue Rs 1,794.16 cr; PAT Rs 388.11 cr

What the numbers show

• Net margin was 21.63% of revenue, up 241 bps from 19.22%.
• Revenue rose 32.5% while total expenses rose 20.9%.
• Cost of materials accounted for Rs 127.37 cr of the Rs 224.14 cr rise in total expenses (56%).
• Other expenses took 26.6% of revenue, against 29.0% a year earlier.

• Basis: Consolidated statement of unaudited financial results for the quarter ended 30-Sep-26 (Q2 FY 2027), with prior comparative quarter ended 30-Sep-25.

• Revenue from operations (Q2 FY27): Rs 1,794.16 cr
• Revenue from operations (Q2 FY26): Rs 1,353.73 cr

• Other income (Q2 FY27): Rs 37.39 cr
• Other income (Q2 FY26): Rs 59.34 cr

• Total income (Q2 FY27): Rs 1,831.55 cr
• Total income (Q2 FY26): Rs 1,413.07 cr

• Cost of materials consumed (Q2 FY27): Rs 344.97 cr
• Cost of materials consumed (Q2 FY26): Rs 217.60 cr

• Purchases of stock-in-trade (Q2 FY27): Rs 80.89 cr
• Purchases of stock-in-trade (Q2 FY26): Rs 53.26 cr

• Changes in inventories of finished goods, work-in-progress and stock-in-trade (Q2 FY27): Rs 14.75 cr
• Changes in inventories of finished goods, work-in-progress and stock-in-trade (Q2 FY26): Rs 45.95 cr

• Employee benefits expense (Q2 FY27): Rs 343.69 cr
• Employee benefits expense (Q2 FY26): Rs 317.01 cr

• Finance costs (Q2 FY27): Rs 2.21 cr
• Finance costs (Q2 FY26): Rs 3.39 cr

• Depreciation and amortisation expense (Q2 FY27): Rs 47.06 cr
• Depreciation and amortisation expense (Q2 FY26): Rs 42.97 cr

• Other expenses (Q2 FY27): Rs 477.80 cr
• Other expenses (Q2 FY26): Rs 392.08 cr

• Total expenses (Q2 FY27): Rs 1,296.40 cr
• Total expenses (Q2 FY26): Rs 1,072.26 cr

• Profit before tax (Q2 FY27): Rs 535.15 cr
• Profit before tax (Q2 FY26): Rs 340.81 cr

• Tax expense (Q2 FY27): Rs 147.04 cr
• Tax expense (Q2 FY26): Rs 80.62 cr

• Profit for the period / PAT (Q2 FY27): Rs 388.11 cr
• Profit for the period / PAT (Q2 FY26): Rs 260.19 cr

• Other comprehensive income (Q2 FY27): Rs 4.87 cr
• Other comprehensive income (Q2 FY26): Rs 8.30 cr

• Total comprehensive income for the period (Q2 FY27): Rs 392.98 cr
• Total comprehensive income for the period (Q2 FY26): Rs 268.49 cr

• Paid-up equity share capital (face value Rs 2 each) (Q2 FY27): Rs 25.47 cr
• Paid-up equity share capital (face value Rs 2 each) (Q2 FY26): Rs 25.07 cr

• Earnings per share – Basic (Q2 FY27): Rs 31.07
• Earnings per share – Basic (Q2 FY26): Rs 20.83

• Earnings per share – Diluted (Q2 FY27): Rs 31.03
• Earnings per share – Diluted (Q2 FY26): Rs 20.82

In the consolidated statement of financial results for the quarter ended 30-Sep-26, Ajanta Pharma reported higher revenue from operations compared with the corresponding quarter ended 30-Sep-25, with total income also increasing over the same period. Expenses rose across major cost lines, including cost of materials consumed, purchases of stock-in-trade, employee benefits expense and other expenses, as shown in the statement of financial results.

Despite the increase in total expenses between Q2 FY26 and Q2 FY27, profit before tax and profit after tax both moved up versus the prior-year quarter, according to the statement of financial results. Basic and diluted earnings per share for the quarter ended 30-Sep-26 were higher than those reported for the quarter ended 30-Sep-25 on the consolidated basis presented.